U.S. Markets closed

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,418.00-29.00 (-0.65%)
At close: 4:35PM BST
Full screen
Previous Close4,447.00
Bid4,413.00 x 6100
Ask4,540.00 x 13000
Day's Range4,388.00 - 4,435.00
52 Week Range3,996.00 - 5,520.00
Avg. Volume2,141,770
Market Cap55.92B
PE Ratio (TTM)16.55
Earnings DateN/A
Dividend & Yield2.79 (4.92%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • MarketWatch8 hours ago

    Champions Oncology shares surge 8% on news of AstraZeneca collaboration

    Champions Oncology Inc. shares surged 8.2% in premarket trade Monday on news of the company's collaboration with AstraZeneca . The companies plan to develop new Patient-Derived Xenograft (PDX) models -- ...

  • Barrons.com3 days ago

    Tesaro: Losing Its Edge?

    The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.

  • Barrons.com3 days ago

    Ovarian Cancer Market Still Up For Grabs

    The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.